Skip to main content

$0.010 (0.00%)

High

$0.01

Low

$0.01

Trades

20

Turnover

$16,459

Volume

1,641,703
30 June 2023 at 4:10pm
Register to track PAB and receive email alerts.

Updated guidance for PAT-DX1 phase 1 clinical study

StockBot

416,823 posts

PAB released this announcement to the ASX on 31 March 2023, 9:01. The announcement is marked as price sensitive, and is 2 page(s) in length and 246kb in size.

You can view all announcements from PAB and see how they appear on a price chart on the announcements page.

At the date of this announcement, PAB was 0.009% short sold according to ASIC data. It was ranked the 580th most shorted stock on the ASX. It remains ranked 630th as of the latest reported data (24 January 2025).

Other Recent Announcements from PAB
PAT-DX1 GLP toxicology reports received 24 May 2023, 9:12
Notification regarding unquoted securities - PAB 11 May 2023, 14:04
Appendix 4C - Quarterly - 31 March 2023 24 April 2023, 10:10
Updated guidance for PAT-DX1 phase 1 clinical study 31 March 2023, 9:01
New PAT-DX3 data demonstrates synthetic lethality 14 March 2023, 9:00
Appendix 4D - Half Year Accounts - 31 December 2022 24 February 2023, 18:15
Application for quotation of securities - PAB 16 February 2023, 13:53
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track PAB and receive email alerts.